SkylineDx announced that the National Comprehensive Cancer Network has updated its Clinical Practice Guidelines in Oncology for Cutaneous Melanoma to recommend Merlin CP-GEP, a clinicopathologic–gene expression profile test, as the first and only molecular assay appropriate for assessing metastatic risk in select early-stage melanoma patients. The update applies to patients with T1b and T2a disease and reflects prospective data showing a materially higher likelihood of sentinel lymph node positivity among patients classified as high risk by the test, placing the assay directly within a guideline-backed clinical decision pathway
The significance of this update lies less in the addition of another diagnostic option and more in the way it redraws the boundary between experimental molecular profiling and guideline-endorsed clinical utility. For more than a decade, melanoma management has wrestled with how to refine sentinel lymph node biopsy decisions in early-stage disease, where the absolute risk of nodal spread is low but the procedural consequences of under- or over-treatment are meaningful. The NCCN’s recognition of Merlin CP-GEP marks a rare moment where molecular risk stratification crosses from observational interest into formal clinical guidance.
How guideline recognition changes the clinical calculus for early-stage melanoma risk stratification
Early-stage melanoma, particularly T1b and T2a disease, occupies a clinical gray zone. Traditional clinicopathologic factors such as Breslow thickness, ulceration status, and mitotic rate provide population-level risk estimates but perform unevenly when applied to individual patients. As a result, sentinel lymph node biopsy has functioned as both a staging tool and a proxy risk assessment, even though most patients undergoing the procedure do not have nodal involvement.
By explicitly naming Merlin CP-GEP as an acceptable tool to support shared decision-making around sentinel lymph node biopsy, the NCCN effectively endorses a shift from anatomy-driven staging alone toward biologically informed risk modeling. This matters because guideline language does not merely validate a technology; it signals to clinicians, payers, and hospital systems that the tool sits within accepted standards of care rather than on the periphery of investigational use.
Industry observers note that this distinction is especially important in melanoma, where prior enthusiasm for gene expression profiling was tempered by inconsistent validation, heterogeneous endpoints, and a lack of prospective blinded data. The NCCN’s decision reflects a judgment that Merlin CP-GEP has cleared a higher evidentiary bar than earlier assays.
What differentiates Merlin CP-GEP from earlier melanoma gene expression profile assays
The melanoma diagnostics field is not new to gene expression profiling. Several assays have been marketed over the years with claims related to recurrence risk or sentinel lymph node positivity. However, regulatory and guideline bodies have consistently drawn a line between prognostic associations and clinically actionable prediction.
Merlin CP-GEP’s differentiation rests on three elements that guideline panels tend to prioritize. First, the assay integrates clinicopathologic variables with gene expression data rather than treating molecular signals in isolation. This hybrid design acknowledges that biology and histopathology are complementary rather than competing sources of risk information.
Second, the test produces a binary high-risk or low-risk output aligned with specific management questions rather than a continuous score that requires post hoc interpretation. For guideline committees, clarity of actionability often matters as much as statistical performance.
Third, and most critically, the NCCN references data from the MERLIN_001 study, described as the largest prospective, blinded trial conducted for a molecular test in cutaneous melanoma. Prospective blinded validation directly addresses one of the central criticisms leveled at earlier gene expression profile assays, which relied heavily on retrospective cohorts and secondary analyses
Why prospective, blinded validation matters more than incremental performance gains
From an analytical standpoint, the reported approximately threefold increase in sentinel lymph node positivity among patients classified as high risk is notable, but not extraordinary on its own. What elevates the finding is the context in which it was generated.
Prospective, blinded study designs reduce selection bias and analytical flexibility, two issues that have historically inflated apparent performance in molecular diagnostics. By locking in endpoints and analysis plans before outcomes are known, such studies provide a clearer signal of real-world predictive value.
Clinicians tracking the melanoma diagnostics space have long expressed skepticism about assays that show promise in curated datasets but falter when deployed across heterogeneous practice settings. The NCCN’s reliance on MERLIN_001 data suggests confidence not only in the magnitude of risk separation but also in the robustness of the evidence supporting it.
This matters because guideline committees are acutely aware that once a test is endorsed, it will be used by physicians with varying levels of expertise and in patient populations that differ from trial cohorts. The bar for reliability is therefore higher than for exploratory tools.
Implications for sentinel lymph node biopsy decision-making and surgical workflows
Sentinel lymph node biopsy carries both clinical and economic consequences. While generally safe, it involves operative risk, potential complications, and downstream imaging or treatment cascades if nodes are positive. Conversely, missing occult nodal disease can delay adjuvant therapy and worsen outcomes.
By providing an additional layer of biologically informed risk assessment, Merlin CP-GEP has the potential to refine patient selection for sentinel lymph node biopsy rather than replace the procedure outright. Regulatory watchers suggest that this positioning aligns well with current surgical oncology practice, which increasingly emphasizes risk stratification over one-size-fits-all interventions.
The test’s binary output may simplify conversations between clinicians and patients, particularly in borderline cases where guideline thresholds are permissive rather than prescriptive. Shared decision-making, a phrase explicitly referenced in the guideline update, reflects a broader shift toward individualized care that balances statistical risk with patient preferences.
What this update signals to payers and reimbursement stakeholders
Guideline inclusion is often a prerequisite, though not a guarantee, for broad reimbursement. Payers frequently look to NCCN recommendations as a benchmark when evaluating coverage decisions, particularly in oncology where off-guideline use can trigger scrutiny.
From a reimbursement perspective, the recognition of Merlin CP-GEP as the only molecular test recommended for this specific use case creates a clearer differentiation in a crowded diagnostics market. Payers may be more inclined to reimburse an assay explicitly named in guidelines than those relegated to investigational status.
At the same time, reimbursement decisions will likely hinge on demonstrated impact on downstream costs. If use of the test leads to fewer unnecessary sentinel lymph node biopsies without compromising outcomes, economic arguments in its favor become stronger. Conversely, if adoption simply adds a diagnostic layer without changing management patterns, payer enthusiasm may be limited.
Competitive pressure on alternative melanoma molecular assays
The NCCN’s explicit statement that alternative gene expression profile assays for sentinel lymph node biopsy risk prediction are not recommended outside of clinical trials introduces a competitive inflection point. For companies offering melanoma molecular diagnostics, the distinction between guideline-recognized and non-recommended tests has immediate commercial implications
Industry observers expect increased pressure on competing assays to generate prospective, blinded data comparable to MERLIN_001. Retrospective validations and registry analyses may no longer suffice to achieve guideline consideration, particularly in light of this precedent.
This dynamic could reshape investment and development priorities within the melanoma diagnostics space, favoring longer, more rigorous studies over rapid commercialization.
Regulatory and adoption considerations beyond guideline endorsement
Although guideline recognition carries weight, it does not resolve all adoption barriers. Laboratory logistics, turnaround times, integration into pathology workflows, and clinician education remain practical considerations.
Merlin CP-GEP is described as a non-invasive test that integrates clinicopathologic inputs with gene expression data, but real-world implementation depends on seamless coordination between surgical pathology and molecular diagnostics laboratories. Institutions without established molecular workflows may face friction in early adoption.
Regulatory watchers also note that while guideline endorsement strengthens the clinical rationale for use, ongoing data generation will remain important. Long-term outcome correlations, particularly regarding survival or recurrence rather than nodal positivity alone, will likely influence how broadly the test is embraced.
What clinicians and regulators are likely to watch next
Following this update, attention will shift to real-world utilization patterns and outcome data. Clinicians will want to see whether Merlin CP-GEP meaningfully changes sentinel lymph node biopsy rates and whether those changes align with patient outcomes.
Regulators and guideline panels may also scrutinize subgroup performance, including how the test behaves across different demographic and biologic melanoma subtypes. Consistency of performance will matter as much as average effect size.
For SkylineDx, continued prospective follow-up from MERLIN_001 and additional validation studies will be central to sustaining guideline confidence and expanding clinical use.
A measured step forward in biologically informed melanoma care
The NCCN’s recommendation of Merlin CP-GEP does not represent a wholesale transformation of melanoma management, but it does mark a meaningful evolution. By formally integrating a molecular assay into early-stage decision-making, the guidelines acknowledge that traditional staging alone has limits and that biology can refine risk in clinically actionable ways.
For the melanoma field, the update sets a higher evidentiary standard for molecular diagnostics while offering clinicians a new, guideline-backed tool to navigate one of the most nuanced decisions in early-stage care. Whether this approach ultimately reduces overtreatment, improves patient experience, or shifts long-term outcomes will depend on how rigorously it is implemented and studied in practice
Merlin CP-GEP becomes first NCCN-endorsed molecular test for early-stage melanoma risk assessment added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →